Search research articles
Contact Us
Filters
Showing results (81-90 of 95) with videos related to
Page
of 10
Sort By:
Experimental Hematology & Oncology
|
June 10, 2026
Multifactorial effects of LGALS1 blockade sensitize tumors to immune checkpoint inhibitor
Jessy John, Mohammad A I Al-Hatamleh, Monika Vashisht, et al.
Journal for Immunotherapy of Cancer
|
July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2019
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
Neil H Segal, Sai-Hong I Ou, Ani Balmanoukian, et al.
Head & Neck
|
April 25, 2020
Transition to a virtual multidisciplinary tumor board during the COVID-19 pandemic: University of Pittsburgh experience
Harish Dharmarajan, Jennifer L Anderson, Seungwon Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma
Dan P Zandberg, Jacob B Allred, Ari J Rosenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sophie Wildsmith, Weimin Li, Song Wu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2018
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P Zandberg, Alain P Algazi, Antonio Jimeno, et al.
Cancer Cell
|
March 14, 2025
Distinct CD8<sup>+</sup> T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Housaiyin Li, Dan P Zandberg, Aditi Kulkarni, et al.
Cancer
|
March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)
Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 8, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
Matthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 95) with videos related to
Sort By:
Page
of 10
Experimental Hematology & Oncology
|
June 10, 2026
Multifactorial effects of LGALS1 blockade sensitize tumors to immune checkpoint inhibitor
Jessy John, Mohammad A I Al-Hatamleh, Monika Vashisht, et al.
Journal for Immunotherapy of Cancer
|
July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2019
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
Neil H Segal, Sai-Hong I Ou, Ani Balmanoukian, et al.
Head & Neck
|
April 25, 2020
Transition to a virtual multidisciplinary tumor board during the COVID-19 pandemic: University of Pittsburgh experience
Harish Dharmarajan, Jennifer L Anderson, Seungwon Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma
Dan P Zandberg, Jacob B Allred, Ari J Rosenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sophie Wildsmith, Weimin Li, Song Wu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2018
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P Zandberg, Alain P Algazi, Antonio Jimeno, et al.
Cancer Cell
|
March 14, 2025
Distinct CD8<sup>+</sup> T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Housaiyin Li, Dan P Zandberg, Aditi Kulkarni, et al.
Cancer
|
March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)
Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 8, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
Matthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Page
of 10